Moderna, Inc. (NASDAQ:MRNA – Get Free Report) fell 8.9% on Wednesday after UBS Group lowered their price target on the stock from $108.00 to $96.00. UBS Group currently has a buy rating on the stock.
Stars like our own Sun produce “superflares” around once every 100 years, surprising astronomers who had previously estimated that such events occurred only every 3000 to 6000 years. The result, from ...
# Duran Humes, also chief executive of Plato Alpha Design, a software consulting firm, told Tribune Business that a recent Inter-American Development Bank (IDB) report had reinforced the view that ...